GloResponse™ CRE-luc2P HEK293 Cell Line

The GloResponse™ CRE-luc2P HEK293 Cell Line is a clonal derivative of Human Embryonic Kidney 293 cells.


 The GloResponse™ CRE-luc2P HEK293 Cell Line is a clonal derivative of Human Embryonic Kidney 293 cells. These cells contain a luciferase gene (luc2P) under the control of a minimal Herpes Simplex Virus (HSV) thymidine kinase promoter with multiple cAMP response elements (CREs). CRE is the DNA-binding sequence for the transcription factor CRE binding protein (CREB), which is responsible for regulation of a variety of biological functions including cell proliferation, circadian rhythms and memory. The GloResponse™ CRE-luc2P HEK293 Cell Line is designed for rapid and convenient analysis of any cellular response that results in modulation of CREB activities.

GPCRs regulate a wide-range of biological functions and are one of the most important target classes for drug discovery. GPCR signaling pathways can be categorized into three classes based on the G protein α-subunit involved: Gs, Gi/o and Gq. The GloResponse™ CRE-luc2P HEK293 Cell Line can be used to study and configure screening assays for Gs- and Gi/o-coupled GPCRs, which signal through cAMP and the cAMP Response Element (CRE).

The GloResponse™ Cell Lines incorporate the improvements developed for the pGL4 family of reporter vectors for enhanced performance. The destabilized luc2P luciferase reporter is used for improved responsiveness to transcriptional dynamics. The luc2P gene is codon optimized for enhanced expression in mammalian cells, and the pGL4 plasmid backbone was engineered to reduce background reporter expression. The result is a cell line with very high induction levels when the pathway of interest is activated.

Features – Benefits

  • Rapid, bioluminescent detection of any cellular response resulting in modulation of CREB activities
Product Size Brand Catalog
GloResponse™ CRE-luc2P HEK293 Cell Line 2 vials Promega E8500


For more specifications, click here

Additional information



There are no reviews yet.

Add your review